Growth signaling aberrations, epigenetic dysregulation, and disruption of cell fate determination define the somatic mutational profile of our patient's tumor, which includes mutations in PIK3R1, KMT2D, and NOTCH1. The gene discussed is KMT2D; the disease is neoplasm.